In obesity and type 2 diabetes, Glut4 glucose transporter expression is decreased selectively in adipocytes 1 . Adipose-specific knockout or overexpression of Glut4 alters systemic insulin sensitivity 2 . Here we show, using DNA array analyses, that nicotinamide N-methyltransferase (Nnmt) is the most strongly reciprocally regulated gene when comparing gene expression in white adipose tissue (WAT) from adiposespecific Glut4-knockout or adipose-specific Glut4-overexpressing mice with their respective controls. NNMT methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor 3, 4 . Nicotinamide is a precursor of NAD
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In obesity and type 2 diabetes, Glut4 glucose transporter expression is decreased selectively in adipocytes 1 . Adipose-specific knockout or overexpression of Glut4 alters systemic insulin sensitivity 2 . Here we show, using DNA array analyses, that nicotinamide N-methyltransferase (Nnmt) is the most strongly reciprocally regulated gene when comparing gene expression in white adipose tissue (WAT) from adiposespecific Glut4-knockout or adipose-specific Glut4-overexpressing mice with their respective controls. NNMT methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor 3, 4 .
Nicotinamide is a precursor of NAD
, an important cofactor linking cellular redox states with energy metabolism 5 . SAM provides propylamine for polyamine biosynthesis and donates a methyl group for histone methylation 6 . Polyamine flux including synthesis, catabolism and excretion, is controlled by the rate-limiting enzymes ornithine decarboxylase (ODC) and spermidine-spermine N 1 -acetyltransferase (SSAT; encoded by Sat1) and by polyamine oxidase (PAO), and has a major role in energy metabolism 7, 8 . We report that NNMT expression is increased in WAT and liver of obese and diabetic mice. Nnmt knockdown in WAT and liver protects against diet-induced obesity by augmenting cellular energy expenditure. NNMT inhibition increases adipose SAM and NAD 1 levels and upregulates ODC and SSAT activity as well as expression, owing to the effects of NNMT on histone H3 lysine 4 methylation in adipose tissue. Direct evidence for increased polyamine flux resulting from NNMT inhibition includes elevated urinary excretion and adipocyte secretion of diacetylspermine, a product of polyamine metabolism. NNMT inhibition in adipocytes increases oxygen consumption in an ODC-, SSAT-and PAO-dependent manner. Thus, NNMT is a novel regulator of histone methylation, polyamine flux and NAD 1 -dependent SIRT1 signalling, and is a unique and attractive target for treating obesity and type 2 diabetes.
Nnmt is expressed at high levels in adipose tissue and liver and at lower levels in other organs 3, 4 . Nnmt is increased in multiple cancers 9, 10 , neurodegenerative diseases 11 , and also in obesity and diabetes [12] [13] [14] . For example, Nnmt expression is increased in adipocytes of obese, compared to nonobese Pima Indians 12 . Metabolomic analyses reveal elevated levels of urinary N 1 -methylnicotinamide, the product of NNMT, in humans with type 2 diabetes, and in db/db mice and obese Zucker rats 13 , indicating increased NNMT activity in obesity and type 2 diabetes. Quantitative trait loci mapping in mice suggests a causative role of Nnmt in type 2 diabetes 14 . Therefore, we investigated the regulation and roles of NNMT in obesity and type 2 diabetes.
Adipose Nnmt messenger RNA levels were increased twofold in insulinresistant adipose-specific Glut4-knockout mice (Fig. 1a) , and reduced by 62% in insulin-sensitive adipose-specific Glut4-overexpressing mice (Fig. 1b) . NNMT protein was increased 1.5-to 2-fold in WAT of ob/ob, db/db mice and high-fat diet (HFD)-fed mice (Fig. 1c-e) , compared with lean, insulin-sensitive controls. Hepatic NNMT protein levels were increased in ob/ob and db/db mice (Fig. 1f, g ) and tended to be higher in HFD-fed mice (Fig. 1h) . Thus, NNMT is upregulated in adipose tissue and liver of mouse models of obesity and insulin resistance.
Adipose and hepatic Nnmt expression varies highly among 25 different mouse strains 15 ( Supplementary Fig. 1 ). Adipose Nnmt expression is high in obesity-prone strains and low in obesity-resistant strains [15] [16] [17] (Supplementary Fig. 1a ). In contrast, liver Nnmt expression does not parallel the propensity for obesity ( Supplementary Fig. 1b ). Adipose Nnmt expression correlates highly with per cent fat mass in diet-induced obesity across 20 different mouse strains 18 , and with expression of retinol-binding protein 4 (Rbp4) (r 5 0.90, P , 0.0001 by Pearson correlation coefficient, two-tailed test), an adipokine that contributes to insulin resistance 2 (Supplementary Fig. 2a, b) . Thus, we proposed that elevated NNMT levels in adipose tissue and/or liver may have a causative role in insulin resistance and obesity.
We knocked down Nnmt with antisense oligonucleotides (ASOs) in HFD-fed mice. ASOs regulate gene expression primarily in liver and fat 19, 20 . Treating HFD-fed mice with Nnmt ASO reduced Nnmt mRNA and NNMT protein by 60 to 75% in WAT and 60% (protein) to 90% (mRNA) in liver ( Fig. 2a-d ), but not in brown adipose tissue and kidney (Fig. 2e, f) . Serum transaminases and creatinine were normal, indicating no hepatic or renal toxicity with ASO treatment ( Supplementary Fig. 3a-c) .
Nnmt knockdown in adipose tissue and liver protected mice from diet-induced obesity (Fig. 2g) , causing a 47% reduction in relative fat mass and a 15% increase in relative lean mass (Fig. 2h, i) . Free body water and hepatic glycogen content were not different (not shown) between control-and Nnmt-ASO-treated mice. Subcutaneous and epididymal fat-pad weights were lower in Nnmt-knockdown mice than in controls (Fig. 2j, k) , largely owing to reduced adipocyte size (44% reduced area, Fig. 2l , and 70% reduced volume, Supplementary Fig. 4 ). Insulin sensitivity was enhanced, as evidenced by approximately 50 to 60% lower serum insulin levels and glucose-insulin product (Fig. 2m, n) . Nnmt knockdown also improved glucose tolerance (Fig. 2o, p) , prevented HFD-induced hepatic steatosis (Fig. 2q, r) , and decreased serum triglycerides and free fatty acids (Supplementary Fig. 5a, b) . Thus, Nnmt knockdown in WAT and liver protects against diet-induced obesity and its deleterious metabolic consequences.
We sought to determine whether the leanness with Nnmt knockdown is due to reduced energy intake or increased energy expenditure. The NNMT substrate, nicotinamide, at pharmacological doses may suppress food intake and cause weight loss in rats 21 . However, Nnmt-ASO-treated mice consumed the same amount of calories as controls (Fig. 3a) . Food intake was measured before body weights diverged, in order to eliminate confounding by body-weight differences. Feed efficiency (body weight change per kcal of food eaten) was reduced by approximately 50% in Nnmt-knockdown mice (Fig. 3b) . Although control-ASO-treated mice gained about 7 mg of fat per kcal of food intake, Nnmt-ASO-treated mice gained no fat (Fig. 3c) . Thus, body weight and fat gain were disproportionally low for the calorie intake in Nnmt-ASO-treated compared with control-ASO-treated mice. Faecal lipid excretion was not changed between control-and Nnmt-ASO-treated mice (Fig. 3d) . Therefore, increased energy expenditure rather than decreased food intake or steatorrhoea explains the leanness in Nnmt-knockdown mice. This was further demonstrated by increased oxygen consumption (expressed per kg body weight or per mouse) during comprehensive laboratory animal monitoring system (CLAMS) analysis performed before body weights started to diverge (Fig. 3e and Supplementary Fig. 6a ). Comparison of mice with similar body weight showed that Nnmt-ASO-treated mice had higher energy expenditure than control-ASO-treated mice ( Supplementary   Fig. 6b ). Energy expenditure per gram of fat mass, but not per gram of lean mass was increased in Nnmt-ASO-treated mice compared with control-ASO-treated mice ( Supplementary Fig. 6c, d ). There was no measurable difference in food intake expressed per mouse or per g body weight, locomotor activity or respiratory exchange ratio (RER) ( Supplementary Fig. 7a-d) . As a third approach to assess the energy 
Figure 1 | NNMT expression is increased in WAT and liver of obese
and insulin-resistant mice. a, b, Nnmt mRNA expression normalized by cyclophilin in WAT of adipose-specific Glut4 knockout (AG4KO) mice and aP2-Cre controls (n 5 4 per group) (a) and adipose-specific Glut4 overexpressing (AG4OX) and wild-type littermate controls (n 5 6 per group) (b). c-e, NNMT protein levels in WAT of ob/ob mice (n 5 8) and lean controls (n 5 4) (c); db/db mice and lean controls (n 5 7 per group) (d), and high-fat diet (HFD)-fed (n 5 6) and chow-fed mice (n 5 7) (e). f-h, NNMT protein levels in liver of ob/ob mice (n 5 9) and lean controls (n 5 6) (f); db/db mice and lean controls (n 5 7 per group) (g); and HFD-fed and chowfed mice (n 5 6 per group) (h). Actin was used as a control for western blot analysis and the levels were not different between lean and obese mice. AU, arbitrary units. Error bars, 6 s.e.m; *P , 0.05. ) in the fed state. o, Intraperitoneal glucose tolerance test. p, Area under the curve (AUC) of the glucose tolerance. q, H&E stain of liver sections of HFD-fed Nnmt-ASOand control-ASO-treated mice, and of chow-fed mice. r, Hepatic triglyceride levels in Nnmt-and control-ASO-treated mice. The scale bars in l and q represent 100 mm; n 5 8 per group for a-p, n 5 13 per group for r. AU, arbitrary units. Error bars, 6 s.e.m.; *P , 0.05.
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expenditure, we measured body weight and body composition before and after an overnight fast. In the absence of energy intake, increased loss of body fat indicates increased energy expenditure. After fasting, Nnmtknockdown mice on HFD lost more body weight, body fat and lean mass than control-ASO-treated mice, and the response resembled that of chow-fed lean mice (Fig. 3f-h ). Core body temperature, BAT weight, and uncoupling protein-1 levels in BAT ( Supplementary Fig. 8a-c) were unchanged. Thus, Nnmt knockdown in WAT and liver increases energy expenditure, and this is likely to be independent of BAT-induced energy dissipation or heat production.
We asked whether NNMT regulates energy expenditure in a cellautonomous manner. Nnmt knockdown in adipocytes led to a 60% increase in oxygen consumption (Fig. 3i) . NNMT inhibition by N 1 -methylnicotinamide-the NNMT reaction product and a specific, potent inhibitor of NNMT at pharmacological doses 3 -also increased oxygen consumption (Fig. 3j) . Conversely, Nnmt overexpression decreased oxygen consumption (Fig. 3k) in adipocytes. Similar results were obtained in cultured hepatoma cells (Supplementary Fig. 9 ). Therefore, NNMT regulates oxygen consumption in a cell-autonomous fashion in both adipocytes and hepatocytes.
We sought to determine the molecular mechanisms for increased energy expenditure with NNMT inhibition. NNMT methylates nicotinamide using SAM as a methyl donor and generates S-adenosylhomocysteine (SAH). Adipose SAM, and the SAM:SAH ratio were increased by 50%
in Nnmt-ASO-treated mice (Fig. 4a) . In liver, SAM was not changed, but the SAM:SAH ratio was increased by 2.2-fold owing to a 48% reduction of SAH levels in Nnmt-ASO-treated mice (Supplementary Fig. 10 ). The unchanged hepatic SAM with Nnmt knockdown contrasts with knockdown of glycine N-methyltransferase (Gnmt), a dominant methyltransferase that accounts for .1% of total cytosolic protein in liver. Gnmt knockdown increases SAM by 40-fold and induces hepatic steatosis and fibrosis 22 . Hepatic Nnmt knockdown did not cause fibrosis as evidenced by normal expression of tissue inhibitor of metalloproteinase 1 (Timp1) and collagen type 1 (Colla1), markers for hepatic fibrosis ( Supplementary Fig. 11a, b) .
SAM has two major functions: first, providing propylamine groups for polyamine biosynthesis; and second, donating methyl groups to substrates including histones 6 . Polyamines (putrescine, spermine and spermidine) are organic polycations that are essential for multiple cellular functions affecting cell growth, cancer and ageing 23 . Polyamine metabolism is tightly controlled (Supplementary Fig. 12 ) 23 . Synthesis is controlled by ODC producing putrescine, and by adenosylmethionine decarboxylase (AMD1) providing decarboxylated SAM for the synthesis of spermidine and spermine. Catabolism is controlled by spermidinespermine . As Nnmt knockdown increases adipose SAM levels (Fig. 4a) , we reasoned that this may cause a 'substrate shunt' of SAM from the NNMT reaction to polyamine flux leading to increased energy expenditure in Nnmt-ASO-treated mice (Fig. 3) . In support of this, Nnmt expression correlates negatively with Odc and Ssat expression in adipose tissue, but not in liver in 25 different mouse strains 15 ( Supplementary Fig. 13a-d) . Nnmt-ASO treatment in vivo augmented adipose ODC and SSAT activity (Fig. 4b, c ) and mRNA expression (Fig. 4d) . The expression of adenosylmethionine decarboxylase Amd1, which provides decarboxylated SAM for spermidine and spermine synthesis, was also increased (Fig. 4d) . In liver, Nnmt ASO increased ODC, but not SSAT activity, or Odc or Ssat expression ( Supplementary Fig. 14a-d) . ODC and SSAT activation drives polyamine flux, which consumes the metabolic substrate, acetyl-CoA, for polyamine acetylation 7 . Consistent with reduced acetyl-CoA availability for lipogenesis, acetyl-CoA carboxylase 1 expression and fatty acid synthase expression and activity were decreased in adipose tissue of Nnmt-ASO-treated mice ( Supplementary Fig. 15a-c) . In addition, adipose Nnmt knockdown also decreased ATP, increased the AMP:ATP ratio and enhanced AMPK threonine 172 phosphorylation ( Supplementary Fig. 16a-d) . Increased urinary diacetylspermine provides direct evidence for enhanced adipose polyamine flux in Nnmt-ASO-treated mice (Fig. 4e) . Furthermore, reduction in Nnmt increased Odc and Ssat expression in cultured adipocytes (Fig. 4f, g) . N 1 -methylnicotinamide treatment promoted diacetylspermine secretion from adipocytes in a dose-dependent manner (Fig. 4h) , complementing the increased urinary diacetylspermine excretion in Nnmt-ASO-treated mice (Fig. 4e) . These data convincingly show that NNMT directly regulates polyamine flux in adipocytes.
In addition to being a substrate for polyamine metabolism, SAM is a methyl donor for numerous methylation reactions including histone methylation, which is important for transcriptional regulation 6 . We measured eight types of histone methylation; the amounts of mono-, di-or tri-methylated lysine 4 of histone H3 (H3K4) were increased in adipose tissue of Nnmt-ASO-treated mice (Fig. 4i) . Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) revealed enrichment of methylated H3K4 on Odc and Ssat genes with NNMT inhibition in adipocytes (Fig. 4j) . Thus, NNMT inhibition modifies histone methylation and increases Odc and Ssat expression, leading to activation of polyamine flux. 
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To determine whether the increased energy expenditure with NNMT inhibition (Fig. 3) is polyamine-dependent, we used N 1 -methylnicotinamide to inhibit NNMT activity in adipocytes. This induced oxygen consumption (Fig. 4k-m) . Knocking down Ssat (Supplementary Fig. 17 ), inhibiting ODC activity 8 or blocking PAO activity abolished N 1 -methylnicotinamideinduced oxygen consumption (Fig. 4k-m) . Thus, NNMT inhibition in adipocytes autonomously enhances oxygen consumption, and this depends on polyamine flux.
The other substrate of the NNMT reaction is nicotinamide, an NAD 1 precursor. Nnmt ASO treatment did not alter adipose and hepatic nicotinamide levels ( Supplementary Fig. 18a, b) . This is likely to be because nicotinamide is metabolized to NAD 1 in a salvage pathway, which is controlled by the rate-limiting enzymes nicotinamide phosphoribosyltransferase (NAMPT) and three isoforms of nicotinamide mononucleotide adenylyltransferase (NMNAT1, NMNAT2 and NMNAT3) 5 .
Nnmt knockdown increased NAD
1 levels per mg of adipose tissue (Fig. 4n ) and the expression of Nampt (Fig. 4o) , cytosolic Nmnat2 and mitochondrial Nmnat3, but not nuclear Nmnat1 (Supplementary Fig. 19 ). NAD 1 is a cofactor of SIRT1 deacetylase activity, and SIRT1 affects energy metabolism 5 . Expression of SIRT1 target genes, including Cd36, catalase (Cat), succinate dehydrogenase B (Sdhb) and growth-arrest and DNAdamage-inducible protein, were increased in adipose tissue of Nnmt-ASO-treated mice [25] [26] [27] [28] (Fig. 4p) , consistent with SIRT1 activation. As
Nnmt-ASO-treated mice are leaner, NAD 1 levels per adipocyte may not be as elevated as per mg of adipose tissue. However, the increased gene expression upstream and downstream of NAD 1 strongly supports enhanced NAD 1 flux in Nnmt-ASO-treated adipocytes. In liver, Nnmt knockdown did not alter NAD 1 levels or the expression of Nampt, Nmnat1, Nmnat2 or Nmnat3 (Supplementary Fig. 20a, b) . In spite of this, Cd36, Cat and SdhB expression was decreased ( Supplementary  Fig. 20c ), indicating reduced SIRT1 activity. Consistent with this, PGC-1a acetylation was enhanced in liver with Nnmt knockdown 29 (Supplementary Fig. 20d ). The decreased hepatic Sirt1 expression ( Supplementary  Fig. 20e ) may contribute to the reduced SIRT1 activity with Nnmt knockdown. Despite the changes in SIRT1 and PGC-1a activity, hepatic Pck1 and G6pc expression were not altered by Nnmt ASO treatment (Supplementary Fig. 21) .
We discovered that NNMT is a novel regulator of adiposity and energy expenditure. This involves modulating adipose SAM and NAD 1 , two fundamental metabolites for energy metabolism. NNMT also regulates hepatic energy metabolism ( Supplementary Fig. 9 ), but most likely with different mechanisms, as Nnmt knockdown did not alter hepatic SAM and NAD 1 levels. In adipocytes, SAM provides substrate for polyamine synthesis, and also modulates Odc and Ssat expression by modifying H3K4 methylation (Fig. 4q) . SAM availability may alter histone methylation in a methylation-site-specific manner rather than affecting global histone methylation 10 . For example, threonine-regulated SAM specifically affects H3K4me3 in mouse embryonic stem cells 30 .
NNMT-regulated H3K4 methylation may have broader effects on gene expression including effects associated with cancer 10 and dementia, conditions in which NNMT activity is enhanced 10, 11 . Activation of adipose polyamine flux causes leanness by catalysing polyamine acetylation to generate acetylpolyamines using acetyl-coA as a metabolic substrate 7 . Acetylpolyamines are oxidized in a futile cycle or excreted in the urine, thereby reducing acetyl-CoA in cells (Fig. 4q and Supplementary Fig. 12 ). Although urinary excretion of acetylpolyamines may not cause significant total-body calorie loss, the metabolic substrate consumption or loss in adipocytes seems to impact systemic e, Urinary diacetylspermine:creatinine ratio (n 5 22 for control-ASO-treated mice; n 5 29 for Nnmt-ASO-treated mice). f, g, Odc and Ssat mRNA levels in 3T3-L1 adipocytes with Nnmt knockdown (n 5 9 per group) (f) and N 1 -methylnicotinamide (me-Nam) (g) treatment (n 5 6 per group). h, Diacetylspermine secretion from 3T3-L1 adipocytes treated with me-Nam (n 5 10 per group). i, Expression of mono-, di-and tri-methylation of lysine histone 3 (H3K4) normalized to total H3 levels in adipose tissue (n 5 8 per group). j, H3K4me2 occupancy on Odc, Ssat genes and an open reading frame free region (Igx1a) as a negative control in adipocytes measured by ChIP-qPCR (n 5 12 per group). k-m, Oxygen consumption in adipocytes transfected with control or Ssat siRNA, and treated with or without 10 mM me-Nam (n 5 6 per group) (k); treated with 10 mM me-Nam with or without 5 mM difluoromethylornithine (DFMO), a specific ODC inhibitor (n 5 6 per group) (l); or treated with 10 mM me-Nam with or without MDL72527, a specific PAO inhibitor (n 5 6 per group) (m). n, NAD 1 levels (n 5 7 Con-ASO; n 5 12 Nnmt ASO). o, mRNA levels of nicotinamide phosphoribosyltransferase (Nampt) (n 5 11 per group). p, mRNA levels of SIRT1 target genes: Cd36, catalase (Cat), succinate dehydrogenase B (SdhB) and growth arrest and DNA-damage-inducible protein (Gadd45a) in adipose tissue of NNMT-ASO-and control-ASO treated mice (n 5 11 per group). Error bars, 6 s.e.m., *P , 0.05, {P 50.06. q, Model of NNMT-regulated energy expenditure in adipocytes. NNMT methylates nicotinamide (Nam), a precursor of NAD 1 , using SAM as a methyl donor. SAM regulates polyamine flux by providing substrates and modulating histone methylation. Polyamine flux utilizes acetyl-CoA to generate acetyl-polyamines, which are oxidized or excreted in the urine. Taken together, this results in adipose metabolic substrate consumption and loss coupled with systemic alteration of energy expenditure.
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energy expenditure. This is clearly demonstrated by leanness and increased energy expenditure in adipose Ssat transgenic mice 24 . Promoting consumption or loss of adipose acetyl-CoA as a metabolic substrate in the form of acetylpolyamines may be a novel strategy for obesity treatment (Fig. 4q) .
NNMT regulates SAM and NAD 1 primarily in adipose tissue, but not in liver, which has redundant regulatory pathways for SAM and NAD 1 metabolism. Hepatic SAM is largely regulated by glycine Nmethyltransferase 22 and by methionine, an abundant SAM precursor in liver. When methionine is abundant, NNMT regulates only SAH, not SAM 10 . Liver NAD 1 synthesis is controlled by a salvage pathway using nicotinamide as a precursor and a de novo pathway using tryptophan 5 . In contrast, adipose tissue barely expresses the key enzymes in the de novo NAD 1 synthesis pathway (data not shown). Therefore, adipose NAD 1 synthesis primarily relies on the salvage pathway using nicotinamide, for which NNMT is the only catabolic enzyme. The adiposeselective effects of NNMT inhibition on SAM and NAD 1 levels are advantageous for drug development because increased SAM in liver causes hepatic steatosis and fibrosis 22 , and increased NAD 1 may enhance hepatic gluconeogenesis 29 . In summary, NNMT is a unique regulator of adiposity by directly altering NAD 1 and SAM, which affect histone methylation, polyamine flux and SIRT1 signalling. NNMT inhibition leads to metabolic substrate consumption or loss from adipocytes coupled with increased energy expenditure in a cell-autonomous manner (Fig. 4q) . These unique features render NNMT an attractive target for treating obesity and type 2 diabetes.
METHODS SUMMARY
Two Nnmt ASOs were selected from 80 ASOs based on Nnmt knockdown efficiency and no hepatic or renal toxicity. Treatment of HFD-fed mice with either of the Nnmt ASOs resulted in leanness. The most potent Nnmt ASO was used for subsequent studies. An ASO (ISIS 425851) with no complementarity to any known gene sequence was used as the control. Nnmt ASOs and control ASOs were injected (37.5 mg kg 21 intraperitoneally) twice per week, starting 2 weeks after initiation of HFD feeding. ODC and SSAT activities were measured under initial rate conditions with non-limiting substrate concentrations as described 8 . Metabolites were measured using high-performance liquid chromatography (HPLC) with mass spectrometry (MS) using isotope dilution or targeted tandem mass spectrometry (LC-MS/MS) 30 . Diacetylspermine was measured using enzyme-linked immunosorbant assay (ELISA; Abnova). Two-tailed student's t-tests were used for single comparisons and analysis of variance (ANOVA) with Bonferroni-Holm post-hoc tests for multiple comparisons. Statistical significance is assumed if P , 0.05. Data are mean 6 s.e.m.
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